Cell-specific aptamers for targeted therapies.
Cell-specific aptamers for targeted therapies.
复制标题
DOI：
10.1007/978-1-59745-557-2_5
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
de Franciscis, Vittorio
中科院分区：
文献类型：
--
作者：
Cerchia, Laura;Giangrande, Paloma H;McNamara, James O;de Franciscis, Vittorio
许多参与细胞生长和分化等不同功能的信号蛋白可以作为致癌基因并引起细胞转化。这些分子代表了癌症诊断或治疗的有吸引力的靶点，因此受到了深入的研究。适配体是小的，高度结构化的核酸分子，通过称为SELEX的程序从组合文库中分离。适配体通过提供嵌入在更大的、明确的三维结构中的有限数量的特定接触点与目标分子结合。最近，针对整个活细胞的适体选择开辟了一条新的途径，它具有三个主要优势：(1)直接选择而无需事先纯化膜结合靶点；(2)获得与体内条件相似的天然构象的膜蛋白；(3)识别与特定表型相关的（新）靶点。培养适体对抗活细胞的能力为新的治疗和递送方法开辟了一些有吸引力的可能性。在本章中，将回顾该领域的最新进展，并详细描述相关的实验方法。
Many signalling proteins involved in diverse functions such as cell growth and differentiation can act as oncogenes and cause cellular transformation. These molecules represent attractive targets for cancer diagnosis or therapy and therefore are subject to intensive investigation. Aptamers are small, highly structured nucleic acid molecules, isolated from combinatorial libraries by a procedure termed SELEX. Aptamers bind to a target molecule by providing a limited number of specific contact points imbedded in a larger, defined three-dimensional structure. Recently, aptamers have been selected against whole living cells, opening a new path which presents three major advantages: (1) direct selection without prior purification of membrane-bound targets, (2) access to membrane proteins in their native conformation similar to the in vivo conditions and (3) identification of (new) targets related to a specific phenotype. The ability to raise aptamers against living cells opens some attractive possibilities for new therapeutic and delivery approaches. In this chapter, the most recent advances in the field will be reviewed together with detailed descriptions of the relevant experimental approaches.